Ticker Details
Innoviva, Inc. Innoviva Inc is a biopharmaceutical company that is engaged in the discovery, development and commercialization of small molecule medicines. The firm collaborates with and receives funding from GlaxoSmithKline.
IPO Date:	November 25, 2008
Sector:	Healthcare
Industry:	Pharma
Market Cap:	$1.64B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.24 | 1.68%
Avg Daily Range (30 D):	$0.38 | 1.67%
Avg Daily Range (90 D):	$0.36 | 1.56%

Institutional Daily Volume
Avg Daily Volume:	.38M
Avg Daily Volume (30 D):	.55M
Avg Daily Volume (90 D):	.5M

Trade Size
Avg Trade Size (Sh.):	89
Avg Trade Size (Sh.) (30 D):	41
Avg Trade Size (Sh.) (90 D):	41

Institutional Trades
Total Institutional Trades:	4,632
Avg Institutional Trade:	$1.83M
Avg Institutional Trade (30 D):	$3.72M
Avg Institutional Trade (90 D):	$3.02M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.94M
Avg Closing Trade (30 D):	$4.91M
Avg Closing Trade (90 D):	$3.89M
Avg Closing Volume:	125.03K

News

Apr 9, 2026 @ 1:55 PM 3 Bargain-Cheap Small Caps Worth a Second Look Source: Chris Markoch

Feb 10, 2026 @ 10:55 AM Tetracyclines Market is Poised to Garner Valuation... Source: Astute Analytica

Jan 8, 2026 @ 3:06 PM Biotech Is Heating Up—These 2 Red-Hot Stock... Source: Nathan Reiff

Aug 7, 2025 @ 3:17 AM Innoviva (INVA) Q2 Sales Jump 64% Source: Na

Dec 16, 2024 @ 6:15 AM Basilea announces agreement with Innoviva Specialt... Source: N/A

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$7.2	$2.52	$2.37
Diluted EPS	$6.02	$2.22	$1.95
Revenue	$420.69M	$97.99M	$114.61M
Gross Profit	$310.19M	$75.83M	$75.67M
Net Income / Loss	$504.34M	$186.6M	$164.15M
Operating Income / Loss	$160.47M	$38.15M	$38.99M
Cost of Revenue	$110.51M	$22.16M	$38.95M
Net Cash Flow	$284M	$52.14M	$74.43M
PE Ratio

Splits
Jun 17, 2013	1:100